Bellerophon Therapeutics, Inc. — Net Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/ede1a8db-1ee9-4344-ab4f-6164d206dfd6/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-19.8M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-005200 |
| FY 2021 | $-17.8M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-004898 |
| FY 2020 | $-24.7M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002768 |
| FY 2019 | $-13.3M | 2019-01-01 – 2019-12-31 | evidence 0001600132-20-000039 |
| FY 2018 | $2.8M | 2018-01-01 – 2018-12-31 | evidence 0001600132-19-000056 |
| FY 2017 | $-54.8M | 2017-01-01 – 2017-12-31 | evidence 0001600132-18-000034 |
| FY 2016 | $-23.8M | 2016-01-01 – 2016-12-31 | evidence 0001600132-18-000034 |
| FY 2015 | $-46.5M | 2015-01-01 – 2015-12-31 | evidence 0001600132-18-000034 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Bellerophon Therapeutics, Inc. — all facts · Operating Income